Already FDA-approved to treat major depression and migraines, TMS can now be marketed as a treatment for obsessive compulsive disorder Santa Barbara, Calif., September 21, 2018 – Transcranial Magnetic Stimulation (TMS) therapy is rapidly growing in popularity as a treatment [..]
TheraMind Services Results
After an average TMS treatment course, TheraMind Service’s patients have experienced significant reduction of their symptoms, as measured by their Beck Depression Inventory (“BDI”) scores. Approximately 60% of TheraMind Services Patients achieve complete remission as measured by a BDI score of less than 10. (Beck scores are a self-reporting series of questions that mental health professionals use to evaluate the intensity, severity and depth of their patients’ depression).
TMS Clinical Studies Results
In a controlled clinical study, one in two patients suffering from depression improved significantly after TMS therapy, and one in three patients were completely free of symptoms after six weeks of treatment. Numerous clinical trials and real world studies have demonstrated that at least 54% of patients experienced a significant improvement in their symptoms and at least 33% of patients experienced complete remission of their symptoms after six weeks.
 Beck scores below 10 are considered normal and indicate that the patient has achieved complete remission.
 Demitrack MA, Thase ME. “Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.” Psychopharm Bull. 2009, 42(2): 5-38. 2.
 In an open-label study, the results of which were confirmed by an independent study sponsored by the National Institute of Mental Health.